Bio-Path Holdings, Inc. (BPTH) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in a report issued on Monday. The brokerage currently has a $1.50 target price on the stock, down from their prior target price of $4.50.

Separately, ValuEngine downgraded shares of Bio-Path Holdings from a sell rating to a strong sell rating in a report on Friday, September 1st.

Shares of Bio-Path Holdings (NASDAQ:BPTH) traded down $0.02 during midday trading on Monday, reaching $0.29. 527,800 shares of the company were exchanged, compared to its average volume of 396,460. Bio-Path Holdings has a 12-month low of $0.25 and a 12-month high of $1.50.

Bio-Path Holdings (NASDAQ:BPTH) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.02). analysts anticipate that Bio-Path Holdings will post -0.08 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/11/14/bio-path-holdings-inc-bpth-receives-buy-rating-from-hc-wainwright.html.

A number of large investors have recently bought and sold shares of BPTH. Bank of New York Mellon Corp raised its position in Bio-Path Holdings by 1.7% during the first quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock worth $257,000 after acquiring an additional 5,172 shares during the period. Legal & General Group Plc raised its position in Bio-Path Holdings by 5,474.3% during the second quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock worth $681,000 after acquiring an additional 1,741,978 shares during the period. HighTower Advisors LLC raised its position in Bio-Path Holdings by 0.3% during the second quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock worth $492,000 after acquiring an additional 4,000 shares during the period. Finally, Sabby Management LLC raised its position in Bio-Path Holdings by 73.2% during the second quarter. Sabby Management LLC now owns 1,190,886 shares of the company’s stock worth $462,000 after acquiring an additional 503,488 shares during the period. Institutional investors own 15.15% of the company’s stock.

Bio-Path Holdings Company Profile

Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.

Receive News & Ratings for Bio-Path Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply